Granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α in combination is a useful diagnostic biomarker to distinguish familial Mediterranean fever from sepsis.


Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
15 10 2021
Historique:
received: 28 07 2021
accepted: 04 10 2021
entrez: 16 10 2021
pubmed: 17 10 2021
medline: 29 10 2021
Statut: epublish

Résumé

To identify potential biomarkers to distinguish familial Mediterranean fever (FMF) from sepsis. We recruited 28 patients diagnosed with typical FMF (according to the Tel Hashomer criteria), 22 patients with sepsis, and 118 age-matched controls. Serum levels of 40 cytokines were analyzed using multi-suspension cytokine array. We performed a cluster analysis of each cytokine in the FMF and sepsis groups in order to identify specific molecular networks. Multivariate classification (random forest analysis) and logistic regression analysis were used to rank the cytokines by importance and determine specific biomarkers for distinguishing FMF from sepsis. Fifteen of the 40 cytokines were found to be suitable for further analysis. Levels of serum granulocyte-macrophage colony-stimulating factor (GM-CSF), fibroblast growth factor 2, vascular endothelial growth factor, macrophage inflammatory protein-1b, and interleukin-17 were significantly elevated, whereas tumor necrosis factor-α (TNF-α) was significantly lower in patients with FMF compared with those with sepsis. Cytokine clustering patterns differed between the two groups. Multivariate classification followed by logistic regression analysis revealed that measurement of both GM-CSF and TNF-α could distinguish FMF from sepsis with high accuracy (cut-off values for GM-CSF = 8.3 pg/mL; TNF-α = 16.3 pg/mL; sensitivity, 92.9%; specificity, 94.4%; accuracy, 93.4%). Determination of GM-CSF and TNF-α levels in combination may represent a biomarker for the differential diagnosis of FMF from sepsis, based on measurement of multiple cytokines.

Identifiants

pubmed: 34654467
doi: 10.1186/s13075-021-02644-2
pii: 10.1186/s13075-021-02644-2
pmc: PMC8518289
doi:

Substances chimiques

Biomarkers 0
Tumor Necrosis Factor-alpha 0
Vascular Endothelial Growth Factor A 0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

260

Informations de copyright

© 2021. The Author(s).

Références

Arthritis Res Ther. 2020 May 7;22(1):108
pubmed: 32381117
Medicine (Baltimore). 2014 May;93(3):158-164
pubmed: 24797171
Crit Care. 2011;15(1):R58
pubmed: 21310070
Hum Mol Genet. 2000 Dec 12;9(20):3001-9
pubmed: 11115844
Front Immunol. 2019 Aug 22;10:1982
pubmed: 31507598
Crit Care. 2007;11(2):R49
pubmed: 17448250
J Surg Res. 1995 Oct;59(4):446-9
pubmed: 7564315
Rheumatology (Oxford). 2016 Dec;55(12):2237-2247
pubmed: 27616144
J Transl Med. 2011 Jul 20;9:113
pubmed: 21774806
J Rheumatol. 2003 Nov;30(11):2422-7
pubmed: 14677188
Clin Rheumatol. 2003 May;22(2):99-101
pubmed: 12740672
Lancet. 1998 Feb 28;351(9103):659-64
pubmed: 9500348
Clin Rheumatol. 2004 Aug;23(4):333-7
pubmed: 15293095
Arthritis Rheum. 1997 Oct;40(10):1879-85
pubmed: 9336425
BMC Immunol. 2020 Jun 15;21(1):35
pubmed: 32539713
J Rheumatol. 2010 Nov;37(11):2369-76
pubmed: 20810496
J Rheumatol. 2004 Nov;31(11):2189-98
pubmed: 15517632
Clin Biochem. 2008 Jul;41(10-11):920-2
pubmed: 18440310
Semin Arthritis Rheum. 1996 Dec;26(3):612-27
pubmed: 8989806
Nat Genet. 1997 Sep;17(1):25-31
pubmed: 9288094
Rheumatol Int. 2006 Jul;26(9):862-4
pubmed: 16397779
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Intensive Care Med. 2002 Jul;28(7):981-4
pubmed: 12122541
Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S77-80
pubmed: 16273770
Sci Rep. 2018 Sep 18;8(1):13995
pubmed: 30228372
Nat Rev Rheumatol. 2018 Oct;14(10):603-618
pubmed: 30218025
Medicine (Baltimore). 2016 Apr;95(16):e3449
pubmed: 27100444
Mod Rheumatol. 2016 Sep;26(5):637-41
pubmed: 26939747
Shock. 2008 Oct;30(4):434-42
pubmed: 18277945
Autoimmun Rev. 2014 Apr-May;13(4-5):388-90
pubmed: 24424166
Front Immunol. 2020 Jul 28;11:1558
pubmed: 32849528
J Rheumatol. 2014 Jun;41(6):1118-23
pubmed: 24786926
Cell. 1997 Aug 22;90(4):797-807
pubmed: 9288758
Rheumatology (Oxford). 2020 Dec 1;59(12):3611-3621
pubmed: 33026080

Auteurs

Tomohiro Koga (T)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. tkoga@nagasaki-u.ac.jp.
Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan. tkoga@nagasaki-u.ac.jp.

Kaori Furukawa (K)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Kiyoshi Migita (K)

Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Shimpei Morimoto (S)

Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan.

Toshimasa Shimizu (T)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan.

Shoichi Fukui (S)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Masataka Umeda (M)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of General Medicine, Nagasaki University Hospital, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Yushiro Endo (Y)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan.

Remi Sumiyoshi (R)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan.

Shin-Ya Kawashiri (SY)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Naoki Iwamoto (N)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Kunihiro Ichinose (K)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Mami Tamai (M)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Tomoki Origuchi (T)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Takahiro Maeda (T)

Department of General Medicine, Nagasaki University Hospital, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Akihiro Yachie (A)

Division of Medical Safety, Kanazawa University Hospital, Kanazawa, Japan.

Atsushi Kawakami (A)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH